GGrantIndex
← Search

Acoustically Activated Micellar Drug Delivery

$350,980R56FY2007EBNIH

University Of Utah, Salt Lake City UT

Investigators

Linked publications & trials

Abstract

The goal of this project is to develop a novel chemotherapeutic modality for the ultrasound image-guided targeted tumor therapy. This is realized by developing a new class of agents that combine the properties of a drug carrier and ultrasound contrast agent in a nano- or micro-particle system. The system comprises a mixture of drug-loaded polymeric micelles and nano- or micro-emulsion droplets stabilized by the same or different biodegradable block copolymer. The nano- or micro-emilsion droplets convert into microbubbles in situ upon heating to physiological temperatures. Upon injection, the drug-loaded polymeric micelles cross the tumor vasculature and accumulate in the tumor interstitium while the microbubbles remain in circulation and can be molecularly targeted to a neovascular endothelium of primary tumors and micrometastases. The designed systems are highly echogenic, which allows contrast-enhanced diagnostic tumor imaging prior to therapy. Following tumor imaging, therapeutic ultrasound is directed to tumor to effectively release drug from the micelles and nano/microbubbles and enhance intracellular drug uptake. The designed microbubbles combine four important functions: (i) drug carriers; (ii) enhancers of drug release from the carrier; enhancers of intracellular drug uptake by tumor cells; and (iii) ultrasound contrast agents. Specific Aims include: 1. Characterize novel imaging/delivery systems with respect to phase state, particle size, drug loading and release. 2. Measure and optimize ultrasound responsiveness (cavitation properties) of drug-loaded microbubbles depending on the type of the stabilizing copolymer, bubble size, and therapeutic ultrasound parameters. 3. Optimize ultrasound parameters and drug delivery properties of the micelle/microparticle systems using breast cancer tumor model. 4. Test and optimize ultrasound imaging properties of the designed systems. 5. Synthesize molecularly targeted nano/microparticle systems by conjugating VEGF to a bubble-stabilizing copolymer. Measure microbubble retention by neovasculature endothelial cells. Relevance: The development of dual-modality imaging/chemotherapy drug delivery systems for use with dual-modality imaging/treatment ultrasound instruments is very timely. The proposed imaging/treatment modality avoids limitations associated with current ultrasonic ablative therapies and is expected to reduce side effects of chemotherapy and enhance treatment outcome and quality of life of cancer patients.

View original record on NIH RePORTER →